Neuraxis inc
NRXS 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
公司發布財報數據季度不足，尚無法提供評分
NRXS 近期報酬表現
8.33%
Neuraxis inc
6.23%
同產業平均
1.02%
S&P500
與 NRXS 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
NNOX | Nano-x imaging ltd | 3 分 | 3 分 | 4 分 | 1 分 | 1 分 | |
ELMD | Electromed, incorporation | 3 分 | 5 分 | 3 分 | 1 分 | 1 分 | |
AORT | Artivion inc | 3 分 | 3 分 | 2 分 | 2 分 | 1 分 | |
MLSS | Milestone scientific inc. | 4 分 | 2 分 | 2 分 | 1 分 | 1 分 | |
BWAY | Brainsway ltd | 4 分 | 2 分 | 2 分 | 1 分 | 1 分 |
- NNOX Nano-x imaging ltd價值 3 分趨勢 3 分波段 4 分籌碼 1 分股利 1 分查看更多
NRXS 公司資訊
Neuraxis, Inc. is a growth-stage company that is primarily focused on developing neuromodulation therapies to address chronic and debilitating conditions in children. The Company is involved in advancing the science with its Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The Company's pipeline B-Stim device is used for the indication of functional abdominal pain associated with irritable bowel syndrome (IBS) and functional nausea in children. The IB-Stim is a PENFS system intended to be used in patients 11-18 years of age with functional abdominal pain associated with IBS. The United States Food and Drug Administration (FDA) pipeline has indications, including chronic nausea, post-concussion syndrome, chemotherapy-induced nausea and vomiting, and cyclic vomiting syndrome.